%0 Journal Article
%A Steinacker, Petra
%A Anderl-Straub, Sarah
%A Diehl-Schmid, Janine
%A Semler, Elisa
%A Uttner, Ingo
%A von Arnim, Christine A F
%A Barthel, Henryk
%A Danek, Adrian
%A Fassbender, Klaus
%A Fliessbach, Klaus
%A Foerstl, Hans
%A Grimmer, Timo
%A Huppertz, Hans-Jürgen
%A Jahn, Holger
%A Kassubek, Jan
%A Kornhuber, Johannes
%A Landwehrmeyer, Bernhard
%A Lauer, Martin
%A Maler, Juan Manuel
%A Mayer, Benjamin
%A Oeckl, Patrick
%A Prudlo, Johannes
%A Schneider, Anja
%A Volk, Alexander E
%A Wiltfang, Jens
%A Schroeter, Matthias L
%A Ludolph, Albert C
%A Otto, Markus
%A group, FTLDc study
%A Albrecht, Franziska
%A Bisenius, Sandrine
%A Feneberg, Emily
%A Haefner, Sibylle
%A Kasper, Elisabeth
%A Kurzwelly, Delia
%A Lampe, Leonie
%A Levin, Johannes
%A Lornsen, Finn
%A Luley, Maxine
%A Oberstein, Timo
%A Pellkofer, Hannah
%A Prix, Catharina
%A Richter-Schmidinger, Tanja
%A Roth, Nina
%A Sabri, Osama
%A Schachner, Lisa
%A Schomburg, Robert
%A Schönecker, Sonja
%A Schuemberg, Katharina
%A Spottke, Annika
%A Teipel, Stefan
%A Wilken, Petra
%A Zech, Heike
%T Serum neurofilament light chain in behavioral variant frontotemporal dementia.
%J Neurology
%V 91
%N 15
%@ 0028-3878
%C [S.l.]
%I Ovid
%M DZNE-2020-06698
%P e1390-e1401
%D 2018
%X Objective: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).Methods: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration–related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry.Results: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91
%K Aged
%K Alzheimer Disease: blood
%K Alzheimer Disease: cerebrospinal fluid
%K Alzheimer Disease: diagnostic imaging
%K Alzheimer Disease: genetics
%K Atrophy
%K Biomarkers: blood
%K Biomarkers: cerebrospinal fluid
%K Brain: pathology
%K Cognitive Dysfunction: blood
%K Cognitive Dysfunction: cerebrospinal fluid
%K Cognitive Dysfunction: diagnostic imaging
%K Cognitive Dysfunction: genetics
%K Diagnosis, Differential
%K Disease Progression
%K Female
%K Follow-Up Studies
%K Frontotemporal Dementia: blood
%K Frontotemporal Dementia: diagnostic imaging
%K Frontotemporal Dementia: genetics
%K Frontotemporal Dementia: pathology
%K Humans
%K Male
%K Middle Aged
%K Mutation
%K Neurofilament Proteins: blood
%K Organ Size
%K Prospective Studies
%K Biomarkers (NLM Chemicals)
%K Neurofilament Proteins (NLM Chemicals)
%K neurofilament protein L (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30209235
%R 10.1212/WNL.0000000000006318
%U https://pub.dzne.de/record/140376